MASH, a chronic and progressive form of fatty liver disease that until recently was known as NASH, affects millions of people in the United States, and its incidence continues to rise. In fact, MASH is now among the leading causes of liver transplantation in the United States. 89bio is developing an experimental therapy to target multiple disease mechanisms of the condition. We spoke to Rohan Palekar, CEO of 89bio, about what’s driving the prevalence of MASH, the limits of existing medicines, and how its experimental therapy targets both liver fibrosis and the underlying metabolic dysfunctions of the disease. Since recording this interview, Roche announced it would acquire 89bio for $14.50 a share and a contingent value right of $6 per share for up to a total of $3.5 billion.